Published in Eur J Immunol on February 01, 1991
The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med (1993) 2.50
Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol (2011) 1.79
Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med (2004) 1.71
Expression of peptidoglycan-associated lipoprotein is required for virulence in the human model of Haemophilus ducreyi infection. Infect Immun (2000) 1.53
The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol (2001) 1.03
CD8+ T cells in human uterine endometrial lymphoid aggregates: evidence for accumulation of cells by trafficking. Immunology (2001) 1.01
Synovial lymphocytes and the aetiology of synovitis. Ann Rheum Dis (1993) 0.97
Presence of CD3+CD8+Bcl-2(low) lymphocytes undergoing apoptosis and activated macrophages in lymph nodes of HIV-1+ patients. Am J Pathol (1995) 0.95
Selective migration of highly differentiated primed T cells, defined by low expression of CD45RB, across human umbilical vein endothelial cells: effects of viral infection on transmigration. Immunology (1997) 0.94
T lymphocyte lines isolated from atheromatous plaque contain cells capable of responding to Chlamydia antigens. Clin Exp Immunol (2000) 0.90
Lymphocyte migration through cultured endothelial cell monolayers derived from the blood-retinal barrier. Immunology (1993) 0.89
Imbalance of CD4+ lymphocyte subsets in patients with mixed connective tissue disease. Clin Exp Immunol (1992) 0.86
MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. Arthritis Res Ther (2011) 0.85
Selective recruitment of lymphocyte subsets to the inflamed appendix. Clin Exp Immunol (1995) 0.83
T lymphocyte adhesion to fibronectin (FN): a possible mechanism for T cell accumulation in the rheumatoid joint. Clin Exp Immunol (1992) 0.82
The role of T cells in rheumatoid arthritis. Clin Rheumatol (1995) 0.81
Analysis of T cell subsets present in the peripheral blood and synovial fluid of reactive arthritis patients. Ann Rheum Dis (1998) 0.81
The inhibitory effect of dexamethasone on lymphocyte adhesion molecule expression and intercellular aggregation is not mediated by lipocortin 1. Clin Exp Immunol (1999) 0.80
Adhesion molecules in rheumatoid arthritis: role in the pathogenesis and prospects for therapy. Ann Rheum Dis (1994) 0.80
Investigation of the cutaneous response to recall antigen in humans in vivo. Clin Exp Immunol (2013) 0.78
Lymphocyte trafficking: CD4 T cells with a 'memory' phenotype (CD45RC-) freely cross lymph node high endothelial venules in vivo. Immunology (1998) 0.78
Thymectomy and azathioprine have no effect on the phenotype of CD4 T lymphocyte subsets in myasthenia gravis. J Neurol Neurosurg Psychiatry (1993) 0.78
The bacterial superantigen Staphylococcal enterotoxin B stimulates lymphocyte locomotor capacity during culture in vitro. Immunology (1996) 0.76
Reactive arthritis-associated bacteria can stimulate lymphocyte proliferation in non-exposed individuals and newborns. Clin Exp Immunol (1995) 0.75
Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med (2001) 7.41
"Lymphokines": non-antibody mediators of cellular immunity generated by lymphocyte activation. Nature (1969) 6.42
Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J (1978) 4.29
Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med (2006) 4.12
Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum (1992) 3.92
An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol (1982) 3.05
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum (1992) 2.68
The sensitivity and specificity of reduced CD8 lymphocyte levels in the diagnosis of polymyalgia rheumatica/giant cell arteritis. Clin Exp Rheumatol (1994) 2.61
HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A (1989) 2.60
A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide. J Immunol (1990) 2.55
HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med (1980) 2.52
Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum (1992) 2.31
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol (1984) 2.17
A role for purine metabolism in the immune response: Adenosine-deaminase activity and deoxyadenosine catabolism. Lancet (1978) 2.15
Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis (1993) 2.01
Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol (1984) 1.95
Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis (2007) 1.73
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis (2007) 1.68
Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis (1989) 1.68
Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med (2000) 1.68
IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Scand J Rheumatol (1983) 1.67
Outpatient lumbar epidural corticosteroid injection in the management of sciatica. Br J Rheumatol (1988) 1.67
B lymphocyte alloantigens in the study of the genetic basis of rheumatoid arthritis. Ann Rheum Dis (1977) 1.65
Analysis of T cell subsets in the peripheral blood and synovial fluid of patients with rheumatoid arthritis by means of monoclonal antibodies. Ann Rheum Dis (1983) 1.64
The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol (2001) 1.62
Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol (1993) 1.57
Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study. Ann Rheum Dis (1987) 1.54
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol (1995) 1.49
Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol (2000) 1.48
Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford) (2003) 1.47
Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis (1994) 1.44
High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients. Rheumatology (Oxford) (2001) 1.40
Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum (1998) 1.39
Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol (1990) 1.38
Influence of pregnancy on disease activity in a patient with palindromic rheumatism. J Rheumatol (1992) 1.38
ELISA assays for IgM and IgG rheumatoid factors. J Immunol Methods (1982) 1.37
Circadian variation in disease activity in rheumatoid arthritis. Br Med J (Clin Res Ed) (1982) 1.30
Human pregnancy serum inhibits interleukin-2 production. Clin Exp Immunol (1984) 1.29
HLA-DRw4 and rheumatoid arthritis. Lancet (1979) 1.29
Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome. Hum Immunol (1991) 1.27
Core antigen-specific immunoglobulin G bound to the liver cell membrane in chronic hepatitis B. Gastroenterology (1982) 1.24
Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Ann Rheum Dis (1983) 1.23
Evidence for the continuous recruitment and activation of T cells into the joints of patients with rheumatoid arthritis. Eur J Immunol (1994) 1.22
Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun (2000) 1.21
Disease activity and pregnancy associated alpha 2-glycoprotein in rheumatoid arthritis during pregnancy. Br Med J (Clin Res Ed) (1983) 1.20
Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol (1990) 1.20
Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter's disease. Arthritis Rheum (1991) 1.19
Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes. Rheumatology (Oxford) (2002) 1.19
The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) (2002) 1.19
Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis (1983) 1.19
Activated T lymphocytes of the synovial membrane in rheumatoid arthritis and other arthropathies. Scand J Immunol (1985) 1.19
Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology (1988) 1.15
Sequence analysis of HLA-DR4B1 subtypes: additional first domain variability is detected by oligonucleotide hybridization and nucleotide sequencing. Hum Immunol (1990) 1.14
In vivo analysis of disease modifying drug therapy activity in rheumatoid arthritis by sequential immunohistological analysis of synovial membrane interleukin 1 beta. J Rheumatol (1994) 1.13
Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J Rheumatol (1991) 1.12
Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum (2002) 1.12
Chemokine production by human chondrocytes. J Rheumatol (1999) 1.12
Expression of HLA-DR, DQ and DP antigens and interleukin-2 receptor on synovial fluid T lymphocyte subsets in rheumatoid arthritis: evidence for "frustrated" activation. J Rheumatol (1987) 1.11
Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis? Clin Exp Immunol (2011) 1.10
Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum (2001) 1.09
The detection of DNA from a range of bacterial species in the joints of patients with a variety of arthritides using a nested, broad-range polymerase chain reaction. Rheumatology (Oxford) (1999) 1.09
Response of rheumatoid-synovial-fluid lymphocytes to non-specific mitogens. Lancet (1973) 1.07
Lymphocyte studies in rheumatoid arthritis. III. A comparative study of the responses of peripheral blood and synovial fluid lymphocytes to phytomitogens. Scand J Rheumatol (1979) 1.07
Anti-LSP antibodies in acute liver disease. Gut (1982) 1.05
Elevated interleukin-8 serum concentrations in beta-thalassemia and graft-versus-host disease. Blood (1993) 1.05
A combined immunohistological and histochemical analysis of lymphocyte and macrophage subpopulations in the rheumatoid nodule. Clin Exp Immunol (1984) 1.05
Detection of immune complexes in serum of patients with ankylosing spondylitis. Ann Rheum Dis (1978) 1.05
Cytokines and the chronic inflammation of rheumatic disease. II. The presence of interleukin-2 in synovial fluids. Clin Exp Immunol (1984) 1.04
HLA-B27 subtypes in the spondarthropathies. Clin Exp Immunol (1993) 1.03
Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis (1981) 1.03
Histocompatibility antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol (1983) 1.02
Action of chloroquine phosphate in rheumatoid arthritis. 1. Immunosuppressive effect. Ann Rheum Dis (1973) 1.02
Clotrimazole in rheumatoid arthritis. Ann Rheum Dis (1980) 1.02
HLA-DR4 restricted lymphocyte proliferation to a Mycobacterium tuberculosis extract in rheumatoid arthritis and healthy subjects. J Immunol (1988) 1.02
Interleukin-10 and interleukin-10 receptor in human osteoarthritic and healthy chondrocytes. Clin Exp Rheumatol (2001) 1.01
Serum and secretory IgA immune response to Klebsiella pneumoniae in ankylosing spondylitis. Clin Rheumatol (1983) 1.01
Patients' views on the quality of health care for rheumatoid arthritis. Rheumatology (Oxford) (2006) 1.01
Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) (2000) 1.00
Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum (1995) 1.00
An improved method for sacro-iliac joint imaging: a study of normal subjects, patients with sacro-iliitis and patients with low back pain. Clin Radiol (1981) 0.99
Simultaneous ligation of CD5 and CD28 on resting T lymphocytes induces T cell activation in the absence of T cell receptor/CD3 occupancy. J Immunol (1993) 0.99
Changes in immune function in patients with rheumatoid arthritis following treatment with sodium aurothiomalate. Ann Rheum Dis (1981) 0.99
Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin Exp Rheumatol (1999) 0.98
Does rheumatoid arthritis have a clinicopathological spectrum similar to that of leprosy? Ann Rheum Dis (1982) 0.98
Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) (2002) 0.98
Abnormal helper-inducer/suppressor-inducer T-cell subset distribution and T-cell activation status are common to all types of chronic synovitis. Scand J Immunol (1988) 0.98
Atopy and rheumatoid arthritis. Clin Allergy (1985) 0.98
Carcinoembryonic antigen in rheumatoid arthritis. Lancet (1974) 0.98
Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum (1996) 0.97
Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol (1993) 0.97
Abnormal lymphocyte reactivity to self-major histocompatibility antigens in rheumatoid arthritis. J Rheumatol (1987) 0.97
Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor. Ann Rheum Dis (1980) 0.97